drugset

drugset / Trial / NCT05289726

Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105

NCT05289726 ↗

Phase 2 Unknown 152 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

RandomizedParallel-groupDouble-blindPrevention

Summary

this is an preventive study to evaluate the preventive effect of traditional chinese medicine TDX105 on Regorafenib induced Dermatologic Toxicities

Timeline

Start: 2022-04-18
Primary completion: 2022-07-18
Completion: 2023-04-18

Publications

Yu S, Hu X, Tan Y, Wang C, Shao Z, Xiao Y, Liu H, Lv J, Li S, Jiang X, Zeng L, Tian A. Prophylactic effect of the traditional Chinese medicine formula danxiong granules (TDX105) on hand-foot skin reaction associated with the antitumor targeted drug regorafenib: a randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2025 Nov 6;16:1641477. doi: 10.3389/fphar.2025.1641477. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TDX105	Traditional medicine (herbal / TCM)	600 ml	Other

Indications